Continuous Bumetanide Infusion For CHF And Renal Failure: A Novel Approach.pdf

This study explores the efficacy of continuous intravenous infusion of bumetanide for severe congestive heart failure (CHF) associated with renal failure. As CHF progresses, it often leads to worsening renal function, exacerbated by standard treatments like renin-angiotensin inhibitors (ACE inhibitors and ARBs), which can cause systemic hypotension and worsen renal inefficiency. These drugs interfere with the renin-angiotensin system, crucial for maintaining sodium chloride reabsorption in the kidneys.

The study highlights that traditional diuretic treatments become less effective as glomerular filtration rate (GFR) decreases due to these inhibitors. Increasing diuretic doses does not necessarily improve diuresis because of reduced drug delivery to renal tubules. The research suggests continuous intravenous infusion of bumetanide, a potent loop diuretic, as an alternative approach.

Bumetanide can be administered orally or via intravenous boluses, but the study emphasizes its effectiveness when given continuously. This method maintains effective drug excretion rates and inhibits sodium chloride reabsorption more consistently than bolus injections. The rationale is that continuous infusion prevents the rapid decline in diuretic efficacy seen with oral or bolus administration, particularly as renal function deteriorates.

The study presents a case where traditional ACE inhibitors like Lisinopril led to rapid renal deterioration, necessitating hemodialysis. It argues against using ACE inhibitors/ARBs in CHF patients with decreased renal function due to their negative impact on GFR and diuretic efficacy. Instead, it proposes continuous bumetanide infusion as a viable treatment for managing fluid overload and alleviating shortness of breath in these patients.

The study was conducted by Anil K. Mandal and published in the Journal of Integrative Cardiology in 2016. It underscores the need for alternative treatments to manage CHF-related symptoms without further compromising renal function.